Plasma Growth Hormone in HCC: A Biomarker of Response to Atezo/Bev?
December 8, 2022
In a new study, researchers investigated the plasma growth hormone as a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. continue reading »